stoxline Quote Chart Rank Option Currency Glossary
  
Lexicon Pharmaceuticals, Inc. (LXRX)
1.7  0.06 (3.66%)    05-30 16:00
Open: 1.67
High: 1.705
Volume: 1,045,907
  
Pre. Close: 1.64
Low: 1.645
Market Cap: 615(M)
Technical analysis
2024-05-30 4:42:53 PM
Short term     
Mid term     
Targets 6-month :  2.13 1-year :  2.38
Resists First :  1.82 Second :  2.03
Pivot price 1.75
Supports First :  1.48 Second :  1.23
MAs MA(5) :  1.65 MA(20) :  1.75
MA(100) :  2.02 MA(250) :  1.77
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  19.2 D(3) :  14.5
RSI RSI(14): 46
52-week High :  3.73 Low :  0.92
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LXRX ] has closed above bottom band by 36.3%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.71 - 1.71 1.71 - 1.72
Low: 1.62 - 1.63 1.63 - 1.64
Close: 1.68 - 1.7 1.7 - 1.71
Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Headline News

Wed, 29 May 2024
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 - WDRB

Tue, 28 May 2024
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much (NASDAQ:LXRX) - Seeking Alpha

Mon, 06 May 2024
Leerink Partnrs Comments on Lexicon Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:LXRX) - Defense World

Mon, 06 May 2024
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript - Yahoo Finance

Sun, 05 May 2024
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript - Seeking Alpha

Thu, 02 May 2024
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -111 (M)
Shares Float 0 (M)
Held by Insiders 2.4624e+008 (%)
Held by Institutions 9.998e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.83
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 11.7 %
Return on Equity (ttm) -40.1 %
Qtrly Rev. Growth 2.31e+006 %
Gross Profit (p.s.) 246.4
Sales Per Share -87
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8536e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio -0.1
Price to Book value -2.05
Price to Sales -0.02
Price to Cash Flow 0
Stock Dividends
Dividend 2.344e+007
Forward Dividend 2.191e+007
Dividend Yield 1378820000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android